Abboud Y et al. Increasing pancreatic cancer incidence in young women in the United States: A population-based time-trend analysis, 2001-2018. Gastroentrology 2023;164(6):978-89.e6. Abstract
Asimgil H et al. Targeting the undruggable oncogenic KRAS: The dawn of hope. JCI Insight 2022;7(1):e153688. Abstract
Bekaii-Saab TS et al. Adagrasib in advanced solid tumors harboring a KRASG12C mutation. J Clin Oncol 2023;[Online ahead of print]. Abstract
Cause for Concern: The rising incidence of early-onset pancreatic cancer. Lancet Gastroenterol Hepatol 2023;8(4):287. Abstract
Conroy T et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817-25. Abstract
De Dosso S et al. Treatment landscape of metastatic pancreatic cancer. Can Treat Rev 2021;96:102180. Abstract
De la Fouchardière C et al. Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 – UCGI 36 – GEMPAX UNICANCER study. ESMO 2022;Abstract LBA60.
Go S-I et al. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). Eur J Cancer 2021;157:21-30. Abstract
Kindler HL et al. Overall survival results from the POLO trial: A phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol 2022;40(34):3929-39. Abstract
O’Kane GM et al. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin Cancer Res 2020;26(18):4901-10. Abstract
O’Reilly EM et al. AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer. ASCO 2023;Abstract 2528.
O’Reilly EM et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020;38(13):1378-88. Abstract
Park W et al. Pancreatic cancer: A review. JAMA 2021;326(9):851-62. Abstract
Picozzi VJ et al. Tumor treating fields (TTFields) concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer: The phase 3 PANOVA-3 study. Gastrointestinal Cancers Symposium 2023;Abstract TPS770.
Qin S et al. Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial. ASCO 2022;Abstract LBA4011.
Rivera F et al. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study. Pancreatology 2019;19(1):64-72. Abstract
Rojas LA et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 2023;618(7963):144-50. Abstract
Strickler JH et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med 2023;388(1):33-43.Abstract
Varghese AM et al. Early-onset pancreas cancer: Clinical descriptors, genomics, and outcomes. J Natl Cancer Inst 2021;113(9):1194-202. Abstract
Von Hoff DD et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691-703. Abstract
Wainberg ZA et al. NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Gastrointestinal Cancers Symposium 2023;Abstract LBA661.
Wang X. NeoTACE: A multicenter, randomized study evaluating the efficacy and safety of neoadjuvant HAIC for TACE plus donafenib in BCLC B stage hepatocellular carcinoma outside of up-to-seven. ASCO 2023;Abstract TPS4186.
Wang-Gillam A et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. Lancet 2016;387(10018):545-57. Abstract
Zaibet S et al. Gemcitabine + nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: A real-world AGEO study. Br J Cancer 2022;126(10):1394-400. Abstract